Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Nelson

Showing results (441-450 of 521) with videos related to

Pageof 53
Sort By:
Contemporary Clinical Trials|March 27, 2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatmentDonna M Evon, Carol E Golin, Paul Stewart, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
The Plant Cell|September 23, 2015
Whole-Genome Resequencing Reveals Extensive Natural Variation in the Model Green Alga Chlamydomonas reinhardtiiJonathan M Flowers, Khaled M Hazzouri, Gina M Pham, et al.
Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.
Hepatology Communications|October 9, 2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET AnalysisKavita Radhakrishnan, Adrian M Di Bisceglie, K Rajender Reddy, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 12, 2022
Pathogen-induced biosynthetic pathways encode defense-related molecules in bread wheatGuy Polturak, Martin Dippe, Michael J Stephenson, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
Antiviral Therapy|March 8, 2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapyVijayan Balan, David R Nelson, Mark S Sulkowski, et al.
Genome Biology and Evolution|April 4, 2025
Chromosome-Level Assemblies of the Allohexaploid Genomes of Conyza sumatrensis and Conyza bonariensisAnthony Côrtes Gomes, Jacob Montgomery, André Lucas Simões Araujo, et al.
Pageof 53

Showing results (441-450 of 521) with videos related to

Sort By:
Pageof 53
Contemporary Clinical Trials|March 27, 2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatmentDonna M Evon, Carol E Golin, Paul Stewart, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
The Plant Cell|September 23, 2015
Whole-Genome Resequencing Reveals Extensive Natural Variation in the Model Green Alga Chlamydomonas reinhardtiiJonathan M Flowers, Khaled M Hazzouri, Gina M Pham, et al.
Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.
Hepatology Communications|October 9, 2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET AnalysisKavita Radhakrishnan, Adrian M Di Bisceglie, K Rajender Reddy, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 12, 2022
Pathogen-induced biosynthetic pathways encode defense-related molecules in bread wheatGuy Polturak, Martin Dippe, Michael J Stephenson, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
Antiviral Therapy|March 8, 2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapyVijayan Balan, David R Nelson, Mark S Sulkowski, et al.
Genome Biology and Evolution|April 4, 2025
Chromosome-Level Assemblies of the Allohexaploid Genomes of Conyza sumatrensis and Conyza bonariensisAnthony Côrtes Gomes, Jacob Montgomery, André Lucas Simões Araujo, et al.
Pageof 53